- Home
- ALLO vs AMBC Comparison
ALLO vs AMBC Comparison
Compare ALLO & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- AMBC
- Stock Information
- Founded
- ALLO 2017
- AMBC 1991
- Country
- ALLO United States
- AMBC United States
- Employees
- ALLO N/A
- AMBC N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- AMBC Property-Casualty Insurers
- Sector
- ALLO Health Care
- AMBC Finance
- Exchange
- ALLO Nasdaq
- AMBC Nasdaq
- Market Cap
- ALLO 545.8M
- AMBC 566.2M
- IPO Year
- ALLO 2018
- AMBC 1991
- Fundamental
- Price
- ALLO $2.69
- AMBC $11.98
- Analyst Decision
- ALLO Buy
- AMBC Strong Buy
- Analyst Count
- ALLO 12
- AMBC 2
- Target Price
- ALLO $10.26
- AMBC $17.00
- AVG Volume (30 Days)
- ALLO 1.7M
- AMBC 512.2K
- Earning Date
- ALLO 10-31-2024
- AMBC 11-05-2024
- Dividend Yield
- ALLO N/A
- AMBC N/A
- EPS Growth
- ALLO N/A
- AMBC N/A
- EPS
- ALLO N/A
- AMBC 1.58
- Revenue
- ALLO $65,000.00
- AMBC $338,000,000.00
- Revenue This Year
- ALLO N/A
- AMBC N/A
- Revenue Next Year
- ALLO $6,292.80
- AMBC N/A
- P/E Ratio
- ALLO N/A
- AMBC $7.58
- Revenue Growth
- ALLO 6.56
- AMBC 5.63
- 52 Week Low
- ALLO $2.01
- AMBC $10.12
- 52 Week High
- ALLO $5.78
- AMBC $18.45
- Technical
- Relative Strength Index (RSI)
- ALLO 49.96
- AMBC 68.33
- Support Level
- ALLO $2.55
- AMBC $10.91
- Resistance Level
- ALLO $2.87
- AMBC $11.35
- Average True Range (ATR)
- ALLO 0.17
- AMBC 0.30
- MACD
- ALLO 0.00
- AMBC 0.11
- Stochastic Oscillator
- ALLO 46.67
- AMBC 91.75
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.